Los Angeles Capital Management LLC Biohaven Pharmaceutical Holding CO Ltd. Transaction History

Los Angeles Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	SELL	$144.95 - $152.29 $95,811 - $100,663	-661 Reduced 13.46%	4,250 $642,000
Q2 2022 Aug 05, 2022	SELL	$83.14 - $145.99 $141,088 - $247,745	-1,697 Reduced 25.68%	4,911 $716,000
Q1 2022 May 06, 2022	BUY	$110.08 - $142.92 $4,403 - $5,716	40 Added 0.61%	6,608 $784,000
Q4 2021 Feb 03, 2022	BUY	$99.73 - $148.48 $655,026 - $975,216	6,568 New	6,568 $905,000
Q2 2021 Aug 05, 2021	SELL	$65.78 - $105.02 $444,015 - $708,885	-6,750 Closed	0 $0
Q1 2021 May 05, 2021	SELL	$64.07 - $91.75 $362,315 - $518,846	-5,655 Reduced 45.59%	6,750 $461,000
Q4 2020 Feb 04, 2021	SELL	$65.07 - $98.24 $976 - $1,473	-15 Reduced 0.12%	12,405 $1.06 Million
Q3 2020 Nov 02, 2020	BUY	$59.04 - $77.95 $74,095 - $97,827	1,255 Added 11.24%	12,420 $807,000
Q2 2020 Aug 05, 2020	BUY	$29.01 - $74.23 $66,287 - $169,615	2,285 Added 25.73%	11,165 $816,000
Q4 2019 Feb 07, 2020	BUY	$40.86 - $57.65 $42,085 - $59,379	1,030 Added 13.12%	8,880 $483,000
Q3 2019 Nov 07, 2019	BUY	$37.38 - $49.47 $293,433 - $388,339	7,850 New	7,850 $328,000

785K

Ticker BHVN
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,645,000
Market Cap $3.65B
Description
Biohaven Pharmaceutical Holding Company Ltd., a biopharmaceutical company, develops products candidates targeting neurological and neuropsychiatric diseases, and rare disorders in the United States. It offers NURTEC ODT (rimegepant) for the acute treatment of migraine, as well as developing Rimegepant for preventive treatment of migraine; Zavege...

Get notified when there are updates to the investment portfolio of Los Angeles Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Los Angeles Capital Management LLC with notifications on news.